{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:08:56Z","timestamp":1781154536685,"version":"3.54.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Cancer Institute Hospital of JFCR."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s11523-026-01204-5","type":"journal-article","created":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T07:36:39Z","timestamp":1773560199000},"page":"269-283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-3859","authenticated-orcid":false,"given":"Takeru","family":"Wakatsuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5856-9668","authenticated-orcid":false,"given":"Naoki","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9714-231X","authenticated-orcid":false,"given":"Shuichi","family":"Hironaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Minashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9923-5309","authenticated-orcid":false,"given":"Shigenori","family":"Kadowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1343-1419","authenticated-orcid":false,"given":"Hidekazu","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8922-5227","authenticated-orcid":false,"given":"Hirokazu","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1399-1918","authenticated-orcid":false,"given":"Toshifumi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2015-8185","authenticated-orcid":false,"given":"Keisho","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1004-8425","authenticated-orcid":false,"given":"Mariko","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4987-1934","authenticated-orcid":false,"given":"Izuma","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4742-0446","authenticated-orcid":false,"given":"Hiroki","family":"Osumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9205-5452","authenticated-orcid":false,"given":"Arisa","family":"Ueki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4041-8298","authenticated-orcid":false,"given":"Shigehisa","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1438-707X","authenticated-orcid":false,"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6887-5709","authenticated-orcid":false,"given":"Kensei","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2492-6014","authenticated-orcid":false,"given":"Daisuke","family":"Takahari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,15]]},"reference":[{"issue":"5","key":"1204_CR1","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1128\/mcb.6.5.1729-1740.1986","volume":"6","author":"DF Stern","year":"1986","unstructured":"Stern DF, Heffernan PA, Weinberg RA. P185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity. Mol Cell Biol. 1986;6(5):1729\u201340. https:\/\/doi.org\/10.1128\/mcb.6.5.1729-1740.1986.","journal-title":"Mol Cell Biol"},{"issue":"5994","key":"1204_CR2","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/312513a0","volume":"312","author":"AL Schechter","year":"1984","unstructured":"Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature. 1984;312(5994):513\u20136. https:\/\/doi.org\/10.1038\/312513a0.","journal-title":"Nature"},{"issue":"2","key":"1204_CR3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.trecan.2023.11.001","volume":"10","author":"C Valenza","year":"2024","unstructured":"Valenza C, Guidi L, Battaiotto E, Trapani D, Sartore Bianchi A, Siena S, et al. Targeting HER2 heterogeneity in breast and gastrointestinal cancers. Trends Cancer. 2024;10(2):113\u201323. https:\/\/doi.org\/10.1016\/j.trecan.2023.11.001.","journal-title":"Trends Cancer"},{"issue":"11","key":"1204_CR4","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783\u201392. https:\/\/doi.org\/10.1056\/NEJM200103153441101.","journal-title":"N Engl J Med"},{"issue":"16","key":"1204_CR5","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J, Suman VJ, Geyer JCE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673\u201384. https:\/\/doi.org\/10.1056\/NEJMoa052122.","journal-title":"N Engl J Med"},{"issue":"9742","key":"1204_CR6","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X.","journal-title":"Lancet"},{"issue":"25","key":"1204_CR7","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2004413.","journal-title":"N Engl J Med"},{"issue":"10418","key":"1204_CR8","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402(10418):2197\u2013208. https:\/\/doi.org\/10.1016\/S0140-6736(23)02033-0.","journal-title":"Lancet"},{"issue":"11","key":"1204_CR9","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1007\/s00535-018-1464-0","volume":"53","author":"T Wakatsuki","year":"2018","unstructured":"Wakatsuki T, Yamamoto N, Sano T, Chin K, Kawachi H, Takahari D, et al. Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer. J Gastroenterol. 2018;53(11):1186\u201395. https:\/\/doi.org\/10.1007\/s00535-018-1464-0.","journal-title":"J Gastroenterol"},{"issue":"3","key":"1204_CR10","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s10120-018-0887-x","volume":"22","author":"S Yagi","year":"2019","unstructured":"Yagi S, Wakatsuki T, Yamamoto N, Chin K, Takahari D, Ogura M, et al. Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer. Gastric Cancer. 2019;22(3):518\u201325. https:\/\/doi.org\/10.1007\/s10120-018-0887-x.","journal-title":"Gastric Cancer"},{"issue":"2","key":"1204_CR11","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s12029-022-00815-1","volume":"54","author":"S Marshall","year":"2023","unstructured":"Marshall S, Wakatsuki T, Takahari D, Matsushima T, Ishizuka N, Nakayama I, et al. Prognostic factors in patients with advanced HER2-positive gastric cancer treated with trastuzumab-based chemotherapy: a cohort study. J Gastrointest Cancer. 2023;54(2):475\u201384. https:\/\/doi.org\/10.1007\/s12029-022-00815-1.","journal-title":"J Gastrointest Cancer"},{"issue":"3","key":"1204_CR12","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s00432-022-03966-7","volume":"149","author":"K Shimozaki","year":"2023","unstructured":"Shimozaki K, Shinozaki E, Yamamoto N, Imamura Y, Osumi H, Nakayama I, et al. KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer. J Cancer Res Clin Oncol. 2023;149(3):1273\u201383. https:\/\/doi.org\/10.1007\/s00432-022-03966-7.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7517","key":"1204_CR13","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research N","year":"2014","unstructured":"Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202\u20139. https:\/\/doi.org\/10.1038\/nature13480.","journal-title":"Nature"},{"issue":"5","key":"1204_CR14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1634\/theoncologist.2014-0378","volume":"20","author":"SM Ali","year":"2015","unstructured":"Ali SM, Sanford EM, Klempner SJ, Rubinson DA, Wang K, Palma NA, et al. Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies. Oncologist. 2015;20(5):499\u2013507. https:\/\/doi.org\/10.1634\/theoncologist.2014-0378.","journal-title":"Oncologist"},{"issue":"1","key":"1204_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/annonc\/mdv508","volume":"27","author":"Y Kuboki","year":"2016","unstructured":"Kuboki Y, Yamashita S, Niwa T, Ushijima T, Nagatsuma A, Kuwata T, et al. Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer. Ann Oncol. 2016;27(1):127\u201333. https:\/\/doi.org\/10.1093\/annonc\/mdv508.","journal-title":"Ann Oncol"},{"issue":"5","key":"1204_CR16","doi-asserted-by":"publisher","first-page":"e756","DOI":"10.1002\/onco.13695","volume":"26","author":"P Yu","year":"2021","unstructured":"Yu P, Wang Y, Yu Y, Wang A, Huang L, Zhang Y, et al. Deep targeted sequencing and its potential implication for cancer therapy in Chinese patients with gastric adenocarcinoma. Oncologist. 2021;26(5):e756\u201368. https:\/\/doi.org\/10.1002\/onco.13695.","journal-title":"Oncologist"},{"key":"1204_CR17","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00135","volume":"6","author":"K Hino","year":"2022","unstructured":"Hino K, Nishina T, Kajiwara T, Bando H, Nakamura M, Kadowaki S, et al. Association of ERBB2 copy number and gene coalterations with trastuzumab efficacy and resistance in human epidermal growth factor receptor 2-positive esophagogastric and gastric cancer. JCO Precis Oncol. 2022;6:e2200135. https:\/\/doi.org\/10.1200\/PO.22.00135.","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"1204_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1158\/2159-8290.CD-17-0787","volume":"8","author":"YY Janjigian","year":"2018","unstructured":"Janjigian YY, Sanchez-Vega F, Jonsson P, Chatila WK, Hechtman JF, Ku GY, et al. Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discov. 2018;8(1):49\u201358. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0787.","journal-title":"Cancer Discov"},{"key":"1204_CR19","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00330","volume":"6","author":"L Zhang","year":"2022","unstructured":"Zhang L, Hamdani O, Gjoerup O, Cho-Phan C, Snider J, Castellanos E, et al. ERBB2 copy number as a quantitative biomarker for real-world outcomes to anti-human epidermal growth factor receptor 2 therapy in advanced gastroesophageal adenocarcinoma. JCO Precis Oncol. 2022;6:e2100330. https:\/\/doi.org\/10.1200\/PO.21.00330.","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"1204_CR20","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/gutjnl-2011-301839","volume":"61","author":"N Deng","year":"2012","unstructured":"Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 2012;61(5):673\u201384. https:\/\/doi.org\/10.1136\/gutjnl-2011-301839.","journal-title":"Gut"},{"issue":"12","key":"1204_CR21","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.1172\/JCI75200","volume":"124","author":"J Kim","year":"2014","unstructured":"Kim J, Fox C, Peng S, Pusung M, Pectasides E, Matthee E, et al. Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. J Clin Investig. 2014;124(12):5145\u201358. https:\/\/doi.org\/10.1172\/JCI75200.","journal-title":"J Clin Investig"},{"issue":"5","key":"1204_CR22","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-17-2781","volume":"24","author":"F Pietrantonio","year":"2018","unstructured":"Pietrantonio F, Fuca G, Morano F, Gloghini A, Corso S, Aprile G, et al. Biomarkers of primary resistance to trastuzumab in HER2-positive metastatic gastric cancer patients: the AMNESIA case-control study. Clin Cancer Res. 2018;24(5):1082\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2781.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1204_CR23","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1634\/theoncologist.2017-0379","volume":"23","author":"A Diaz-Serrano","year":"2018","unstructured":"Diaz-Serrano A, Angulo B, Dominguez C, Pazo-Cid R, Salud A, Jimenez-Fonseca P, et al. Genomic profiling of HER2-positive gastric cancer: PI3K\/Akt\/mTOR pathway as predictor of outcomes in HER2-positive advanced gastric cancer treated with trastuzumab. Oncologist. 2018;23(9):1092\u2013102. https:\/\/doi.org\/10.1634\/theoncologist.2017-0379.","journal-title":"Oncologist"},{"issue":"6","key":"1204_CR24","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1007\/s10120-019-00973-5","volume":"22","author":"D Takahari","year":"2019","unstructured":"Takahari D, Chin K, Ishizuka N, Takashima A, Minashi K, Kadowaki S, et al. Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naive, HER2-positive advanced gastric cancer. Gastric Cancer. 2019;22(6):1238\u201346. https:\/\/doi.org\/10.1007\/s10120-019-00973-5.","journal-title":"Gastric Cancer"},{"issue":"6","key":"1204_CR25","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s10147-024-02509-z","volume":"29","author":"T Wakatsuki","year":"2024","unstructured":"Wakatsuki T, Ishizuka N, Hironaka S, Minashi K, Kadowaki S, Goto M, et al. Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumab. Int J Clin Oncol. 2024;29(6):801\u201312. https:\/\/doi.org\/10.1007\/s10147-024-02509-z.","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"1204_CR26","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10147-011-0197-3","volume":"16","author":"T Wakatsuki","year":"2011","unstructured":"Wakatsuki T, Irisawa A, Terashima M, Shibukawa G, Takagi T, Imamura H, et al. ATP assay-guided chemosensitivity testing for gemcitabine with biopsy specimens obtained from unresectable pancreatic cancer using endoscopic ultrasonography-guided fine-needle aspiration. Int J Clin Oncol. 2011;16(4):387\u201394. https:\/\/doi.org\/10.1007\/s10147-011-0197-3.","journal-title":"Int J Clin Oncol"},{"issue":"19","key":"1204_CR27","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2013.53.6136","volume":"32","author":"T Satoh","year":"2014","unstructured":"Satoh T, Xu RH, Chung HC, Sun GP, Doi T, Xu JM, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. J Clin Oncol. 2014;32(19):2039\u201349. https:\/\/doi.org\/10.1200\/JCO.2013.53.6136.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1204_CR28","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1158\/1078-0432.CCR-14-2659","volume":"21","author":"CY Ock","year":"2015","unstructured":"Ock CY, Lee KW, Kim JW, Kim JS, Kim TY, Lee KH, et al. Optimal patient selection for trastuzumab treatment in HER2-positive advanced gastric cancer. Clin Cancer Res. 2015;21(11):2520\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2659.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1204_CR29","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/1078-0432.CCR-22-2533","volume":"29","author":"F Pietrantonio","year":"2023","unstructured":"Pietrantonio F, Manca P, Bellomo SE, Corso S, Raimondi A, Berrino E, et al. HER2 copy number and resistance mechanisms in patients with HER2-positive advanced gastric cancer receiving initial trastuzumab-based therapy in JACOB trial. Clin Cancer Res. 2023;29(3):571\u201380. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2533.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1204_CR30","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41591-018-0022-x","volume":"24","author":"GS Wong","year":"2018","unstructured":"Wong GS, Zhou J, Liu JB, Wu Z, Xu X, Li T, et al. Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med. 2018;24(7):968\u201377. https:\/\/doi.org\/10.1038\/s41591-018-0022-x.","journal-title":"Nat Med"},{"issue":"12","key":"1204_CR31","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1158\/2159-8290.CD-15-0748","volume":"5","author":"EL Kwak","year":"2015","unstructured":"Kwak EL, Ahronian LG, Siravegna G, Mussolin B, Borger DR, Godfrey JT, et al. Molecular heterogeneity and receptor coamplification drive resistance to targeted therapy in MET-amplified esophagogastric cancer. Cancer Discov. 2015;5(12):1271\u201381. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0748.","journal-title":"Cancer Discov"},{"issue":"3","key":"1204_CR32","doi-asserted-by":"publisher","first-page":"293","DOI":"10.21873\/cdp.10107","volume":"2","author":"N Nakamura","year":"2022","unstructured":"Nakamura N, Kaida D, Tomita Y, Miyata T, Miyashita T, Fujita H, et al. Intra-tumoral FGFR2 expression predicts prognosis and chemotherapy response in advanced HER2-positive gastric cancer patients. Cancer Diagn Progn. 2022;2(3):293\u20139. https:\/\/doi.org\/10.21873\/cdp.10107.","journal-title":"Cancer Diagn Progn"},{"issue":"1","key":"1204_CR33","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.1634\/theoncologist.2020-0509","volume":"26","author":"DL Jardim","year":"2021","unstructured":"Jardim DL, Millis SZ, Ross JS, Woo MS, Ali SM, Kurzrock R. Cyclin pathway genomic alterations across 190,247 solid tumors: leveraging large-scale data to inform therapeutic directions. Oncologist. 2021;26(1):e78\u20139. https:\/\/doi.org\/10.1634\/theoncologist.2020-0509.","journal-title":"Oncologist"},{"key":"1204_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/srep09289","volume":"5","author":"JY Lee","year":"2015","unstructured":"Lee JY, Hong M, Kim ST, Park SH, Kang WK, Kim KM, et al. The impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in HER2-positive gastric cancer. Sci Rep. 2015;5:9289. https:\/\/doi.org\/10.1038\/srep09289.","journal-title":"Sci Rep"},{"issue":"4","key":"1204_CR35","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.humpath.2013.11.004","volume":"45","author":"R Tajiri","year":"2014","unstructured":"Tajiri R, Ooi A, Fujimura T, Dobashi Y, Oyama T, Nakamura R, et al. Intratumoral heterogeneous amplification of ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple ligation-dependent probe amplification and fluorescence in situ hybridization. Hum Pathol. 2014;45(4):725\u201334. https:\/\/doi.org\/10.1016\/j.humpath.2013.11.004.","journal-title":"Hum Pathol"},{"issue":"6","key":"1204_CR36","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/modpathol.2015.33","volume":"28","author":"A Ooi","year":"2015","unstructured":"Ooi A, Oyama T, Nakamura R, Tajiri R, Ikeda H, Fushida S, et al. Semi-comprehensive analysis of gene amplification in gastric cancers using multiplex ligation-dependent probe amplification and fluorescence in situ hybridization. Mod Pathol. 2015;28(6):861\u201371. https:\/\/doi.org\/10.1038\/modpathol.2015.33.","journal-title":"Mod Pathol"},{"issue":"3","key":"1204_CR37","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s10120-016-0627-z","volume":"20","author":"Y Deguchi","year":"2017","unstructured":"Deguchi Y, Okabe H, Oshima N, Hisamori S, Minamiguchi S, Muto M, et al. PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma. Gastric Cancer. 2017;20(3):416\u201327. https:\/\/doi.org\/10.1007\/s10120-016-0627-z.","journal-title":"Gastric Cancer"},{"issue":"1","key":"1204_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11447-4","volume":"23","author":"Y Kim","year":"2023","unstructured":"Kim Y, Bae YJ, Kim JH, Kim H, Shin SJ, Jung DH, et al. Wnt\/\u03b2-catenin pathway is a key signaling pathway to trastuzumab resistance in gastric cancer cells. BMC Cancer. 2023;23(1):922. https:\/\/doi.org\/10.1186\/s12885-023-11447-4.","journal-title":"BMC Cancer"},{"issue":"11","key":"1204_CR39","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nrc1208","volume":"3","author":"PM Siegel","year":"2003","unstructured":"Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer. 2003;3(11):807\u201321. https:\/\/doi.org\/10.1038\/nrc1208.","journal-title":"Nat Rev Cancer"},{"key":"1204_CR40","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251367344","volume":"17","author":"H Osumi","year":"2025","unstructured":"Osumi H, Wakatsuki T, Ooki A, Chin K, Shoji H, Ogura M, et al. Clinical relevance of circulating tumor DNA in HER2-positive advanced gastric cancer: a collaborative study of a phase Ib trial of dual HER2 and PD-1 targeted therapy (Ni-High). Ther Adv Med Oncol. 2025;17:17588359251367344. https:\/\/doi.org\/10.1177\/17588359251367344.","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"1204_CR41","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1200\/JCO.2015.62.6598","volume":"34","author":"JR Hecht","year":"2016","unstructured":"Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO, et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013\/LOGiC: a randomized phase III trial. J Clin Oncol. 2016;34(5):443\u201351. https:\/\/doi.org\/10.1200\/JCO.2015.62.6598.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1204_CR42","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S1470-2045(17)30111-0","volume":"18","author":"PC Thuss-Patience","year":"2017","unstructured":"Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2\/3 study. Lancet Oncol. 2017;18(5):640\u201353. https:\/\/doi.org\/10.1016\/S1470-2045(17)30111-0.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1204_CR43","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/S1470-2045(18)30481-9","volume":"19","author":"J Tabernero","year":"2018","unstructured":"Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018;19(10):1372\u201384. https:\/\/doi.org\/10.1016\/S1470-2045(18)30481-9.","journal-title":"Lancet Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01204-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01204-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01204-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:57:51Z","timestamp":1774630671000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01204-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1204"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01204-5","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shuichi Hironaka reports personal frees from Taiho and Chugai. Keiko Minashi reports grants from Taiho. Shigenori Kadowaki reports personal fees from Chugai and Taoho, as well as grants from Chugai. Hidekazu Hirano reports personal fees from Toiho and grants from Taiho. Izuma Nakayama reports personal fees from Taiho and Chugai, as well as grants from Chugai. Shigehisa Kitano reports personal fees from Taiho and Chugai, as well as grants from Chugai. Narikazu Boku reports personal fees from Taiho and Chugai. Kensei Yamaguchi reports personal fees from Taiho and Chugai, as well as grants from Taiho. Daisuke Takahari reports personal fees from Taiho, Chugai, and Yakult. Takeru Wakatsuki, Noriko Yamamoto, Naoki Ishizuka, Hirokazu Shoji, Toshifumi Yamaguchi, Keisho Chin, Mariko Ogura, Hiroki Osumi, and Arisa Ueki have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and Ethical Guidelines for Clinical Studies in Japan. The study protocol was approved by the Ethics Committees of The Cancer Institute Hospital and those of each participating center before initiating enrollment (2015\u201327).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent for participation in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All patients provided written informed consent for publication of both the clinical trial and this collaborative study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data generated in this study are not publicly available because of restrictions related to participant consent but is available upon reasonable request from the corresponding author.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization: TW; resources: TW, SH, KM, SK, HH, HS, KC, MO, IN, TY, DT, KY; data curation: TW; formal analysis: TW, NI; funding acquisition: KY; investigation: TW, NY; methodology: NB, NI, AU, SK, HH, HO; visualization: TW, NB; project administration: TW, DT; writing (original draft): TW; writing (review and editing: NB, AU, SH, KM, SK, HO, HH, SK, DT; supervision: KY.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}